NCT01490788View on ClinicalTrials.gov

A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 18, 2011

Primary Completion Date

December 30, 2011

Study Completion Date

December 30, 2011

Conditions
Healthy
Interventions
DRUG

Treatment A

TNX-102 2.4 mg - 1 gelcap once under fasting conditions.

DRUG

Treatment B

Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions

DRUG

Treatment C

TNX-102 2.4 mg, 1 gelcap once given under fed conditions.

Trial Locations (1)

G1P 0A2

PharmaNet, Inc., Québec

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT01490788 - A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults. | Biotech Hunter | Biotech Hunter